Infinity Pharmaceuticals, Inc.
INFI wurde am 13. September 2023 von der Börse genommen.
Profil: Infinity Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology related treatments. The company operates in only one segment which is drug development.
Mitarbeiter: 30
Nachrichten
Für INFI liegen uns keine aktuellen Nachrichtenartikel vor.